Volpara Health said the 200th peer-reviewed paper has been published on the use of its Volpara AI technology.
Since it was established in 2009, the company has been involved with several high-profile personalized screening and optimization studies, such as the DENSE, TOMM2, and To-Be trials, and the PROCAS I/II and KARMA studies.
Volpara's technology was also used to add volumetric breast density to the Tyrer-Cuzick breast cancer risk prediction model.
The company's research goals include understanding the impact of automated image quality metrics on screening outcomes, refining TruDensity measures, and expanding its use to other modalities, and improving understanding of breast density change to improve breast cancer risk prediction and response to drugs.
